Karyopharm Therapeutics Inc. (KPTI): Price and Financial Metrics
GET POWR RATINGS... FREE!
KPTI POWR Grades
- KPTI scores best on the Value dimension, with a Value rank ahead of 72.76% of US stocks.
- The strongest trend for KPTI is in Quality, which has been heading up over the past 177 days.
- KPTI ranks lowest in Stability; there it ranks in the 2nd percentile.
KPTI Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for KPTI is -9.43 -- better than only 1.81% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -3.2 for KARYOPHARM THERAPEUTICS INC; that's greater than it is for just 3.77% of US stocks.
- Revenue growth over the past 12 months for KARYOPHARM THERAPEUTICS INC comes in at -25.14%, a number that bests merely 7.74% of the US stocks we're tracking.
- Stocks that are quantitatively similar to KPTI, based on their financial statements, market capitalization, and price volatility, are INSG, CHRS, DBX, ATNX, and LGVN.
- Visit KPTI's SEC page to see the company's official filings. To visit the company's web site, go to www.karyopharm.com.
KPTI Valuation Summary
- In comparison to the median Healthcare stock, KPTI's price/sales ratio is 48.94% lower, now standing at 2.4.
- KPTI's price/sales ratio has moved down 1020.5 over the prior 114 months.
Below are key valuation metrics over time for KPTI.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| KPTI | 2023-03-24 | 2.4 | -22.6 | -2.3 | -3.0 |
| KPTI | 2023-03-23 | 2.3 | -21.9 | -2.2 | -2.9 |
| KPTI | 2023-03-22 | 2.3 | -22.0 | -2.2 | -2.9 |
| KPTI | 2023-03-21 | 2.5 | -23.7 | -2.4 | -3.1 |
| KPTI | 2023-03-20 | 2.5 | -24.0 | -2.4 | -3.2 |
| KPTI | 2023-03-17 | 2.5 | -23.1 | -2.3 | -3.1 |
KPTI Growth Metrics
- The 4 year net cashflow from operations growth rate now stands at -96.91%.
- The 3 year revenue growth rate now stands at 1043.08%.
- Its 4 year cash and equivalents growth rate is now at 682.73%.
The table below shows KPTI's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-12-31 | 157.074 | -149.554 | -165.291 |
| 2022-09-30 | 249.763 | -97.236 | -88.065 |
| 2022-06-30 | 251.307 | -92.821 | -103.553 |
| 2022-03-31 | 234.229 | -113.425 | -108.073 |
| 2021-12-31 | 209.819 | -107.116 | -124.088 |
| 2021-09-30 | 118.65 | -163.225 | -206.229 |
KPTI's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- KPTI has a Quality Grade of C, ranking ahead of 58.11% of graded US stocks.
- KPTI's asset turnover comes in at 0.338 -- ranking 138th of 681 Pharmaceutical Products stocks.
- CAPR, DRNA, and PLXP are the stocks whose asset turnover ratios are most correlated with KPTI.
The table below shows KPTI's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.338 | 0.965 | -0.614 |
| 2021-03-31 | 0.347 | 0.975 | -0.545 |
| 2020-12-31 | 0.299 | 0.975 | -0.534 |
| 2020-09-30 | 0.255 | 0.967 | -0.576 |
| 2020-06-30 | 0.239 | 0.956 | -0.607 |
| 2020-03-31 | 0.189 | 0.945 | -0.671 |
KPTI Price Target
For more insight on analysts targets of KPTI, see our KPTI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.22 | Average Broker Recommendation | 1.6 (Moderate Buy) |
KPTI Stock Price Chart Interactive Chart >
KPTI Price/Volume Stats
| Current price | $3.51 | 52-week high | $8.63 |
| Prev. close | $3.49 | 52-week low | $2.45 |
| Day low | $3.44 | Volume | 2,177,123 |
| Day high | $3.63 | Avg. volume | 2,685,256 |
| 50-day MA | $3.28 | Dividend yield | N/A |
| 200-day MA | $4.35 | Market Cap | 397.83M |
Karyopharm Therapeutics Inc. (KPTI) Company Bio
Karyopharm Therapeutics is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The company was founded in 2008 and is based in in Newton, Massachusetts.
Latest KPTI News From Around the Web
Below are the latest news stories about KARYOPHARM THERAPEUTICS INC that investors may wish to consider to help them evaluate KPTI as an investment opportunity.
Karyopharm Announces Updated Selinexor Data in Patients with Treatment-Naïve Myelofibrosis to be Presented at AACR 2023Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that results from its Phase 1 study evaluating the safety and efficacy of once-weekly selinexor in combination with standard dose ruxolitinib in patients with treatment-naïve myelofibrosis (NCT04562389) have been selected for a poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, being held April 14-19, 2023 in Orland |
Karyopharm to Participate at Barclays Global Healthcare ConferenceKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Barclays Global Healthcare Conference in a fireside chat on Wednesday, March 15 at 4:35 p.m. ET. |
Karyopharm Therapeutics (NASDAQ:KPTI) shareholders have endured a 87% loss from investing in the stock three years agoIt's not possible to invest over long periods without making some bad investments. But really bad investments should be... |
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 111,250 restricted stock units (RSUs) to eight newly-hired employees. These RSU awards were granted as of February 28, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing R |
Karyopharm and Menarini Group Receive Full Marketing Authorization from the UK Medicines & Healthcare Products Regulatory Agency for NEXPOVIO® (selinexor) in Combination with Bortezomib and Dexamethasone for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior TherapyKaryopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the United Kingdom's (UK) Medicines and Healthcare Products Regulatory Agency (MHRA) has granted full Marketing Authorization for NEXPOVIO® (selinexor), a first-in-class, oral exportin 1 (XPO1) inhibitor, in combination with once-weekly bortezomib (Velcade® |
KPTI Price Returns
| 1-mo | 17.00% |
| 3-mo | 31.46% |
| 6-mo | -34.64% |
| 1-year | -51.52% |
| 3-year | -82.07% |
| 5-year | -73.85% |
| YTD | 3.24% |
| 2022 | -47.12% |
| 2021 | -58.46% |
| 2020 | -19.25% |
| 2019 | 104.59% |
| 2018 | -2.40% |
Continue Researching KPTI
Want to see what other sources are saying about Karyopharm Therapeutics Inc's financials and stock price? Try the links below:Karyopharm Therapeutics Inc (KPTI) Stock Price | Nasdaq
Karyopharm Therapeutics Inc (KPTI) Stock Quote, History and News - Yahoo Finance
Karyopharm Therapeutics Inc (KPTI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...